Preoperative staging of primary breast cancer.A multicentric study

Ciatto, Stefano; Pacini, P; Azzini, Vincenzo; Néri, A.; Jannini, Annamaria; Gosso, P; Molino, Annamaria; Capelli, Maria Carla; Costanzo, Francesco Di; Pucciatti, M. Assunta; Andreoli, C; Santoro, Giuseppe; Farante, G.; Ciurli, Massimo; Costa, A. Ramos da; Brignone, G.; Ravaioli, Alberto; Scarpellini, M; Rosetti, Paolo; Leo, Giuseppe; Punzo, Clelia; Oliva, Vincenzo

doi:10.1002/1097-0142(19880301)61:5<1038::aid-cncr2820610530>3.0.co;2-z

Cited by 63 publications

(10 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For patients with stage I, II, and III disease, bone metastasis rate is ranged from 0.1-6.8%, 0.8-8.8%, and 1.2-24.5% [1,2,4,22,23]. Those studies support that a BS is necessary for T3N1M0 and stage II/III patients with skeletal symptoms (such as pain and increased alkaline phosphatase).…”

Section: Discussionmentioning

confidence: 81%

Baseline staging tests based on molecular subtype is necessary for newly diagnosed breast cancer

Chen

Sun

Cong

et al. 2014

J Exp Clin Cancer Res

View full text Add to dashboard Cite

BackgroundBone scanning (BS), liver ultrasonography (LUS), and chest radiography (CXR) are commonly recommended for baseline staging in patients with newly diagnosed breast cancer. The purpose of this study is to demonstrate whether these tests are indicated for specific patient subpopulation based on clinical staging and molecular subtype.MethodsA retrospective study on 5406 patients with newly diagnosed breast cancer was conducted to identify differences in occurrence of metastasis based on clinical staging and molecular subtypes. All patients had been evaluated by BS, LUS and CXR at diagnosis.ResultsComplete information on clinical staging was available in 5184 patients. For stage I, II, and III, bone metastasis rate was 0%, 0.6% and 2.7%, respectively (P < 0.01); liver metastasis rate was 0%, 0.1%, and 1.0%, respectively (P < 0.01); lung metastasis rate was 0.1%, 0.1%, and 0.7%, respectively (P < 0.01). Complete information on molecular subtype was available in 3411 patients. For Luminal A, Luminal B (HER2-), Luminal BH (HER2+), HER2+ overexpression, and Basal-like, bone metastasis rate was 1.4%, 0.7%, 2.5%, 2.7%, and 0.9%, respectively (P < 0.05); liver metastasis rate was 0.1%, 0.1%, 1.0%, 1.1%, and 0.9%, respectively (P < 0.01); lung metastasis rate was 0.20%, 0%, 0%, 0.27%, and 0.9%, respectively (P < 0.05). cT (tumor size), cN (lymph node), PR (progesterone receptor), and HER2 status predicted bone metastasis (P < 0.05). cT, cN, ER (estrogen receptor), PR, and HER2 status predicted liver metastasis (P < 0.05). cT, cN, and PR status predicted lung metastasis (P < 0.05).ConclusionThese data indicate that based on clinical staging and molecular subtypes, BS, LUS and CXR are necessary for patients with newly diagnosed breast cancer.

show abstract

Section: Discussionmentioning

confidence: 81%

Baseline staging tests based on molecular subtype is necessary for newly diagnosed breast cancer

Chen

Sun

Cong

et al. 2014

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…Schneider et al [7] found that the overall rate of distant metastasis was only 3.9%, and several papers have reported the detection rates of individual staging investigations. For isotope bone scan this has been published as 0.5–11% [5, 7, 18–23], for liver ultrasound 0.24–3.3% [5, 7, 20, 24], and for chest radiography 0.2–1.2% [7, 18, 20, 25, 26]. …”

Section: Discussionmentioning

confidence: 99%

Staging Investigations in Breast Cancer: Collective Opinion of UK Breast Surgeons

Chand

Cutress

Oeppen

et al. 2013

International Journal of Breast Cancer

View full text Add to dashboard Cite

Introduction. Certain clinicopathological factors are associated with a higher likelihood of distant metastases in primary breast cancer. However, there remains inconsistency in which patients undergo formal staging for distant metastasis and the most appropriate investigation(s). Aims. To identify UK surgeon preferences and practice with regard to staging investigations for distant metastases. Methods. A survey was disseminated to members of the Association of Breast Surgery by e-mail regarding surgeon/breast unit demographics, use of staging investigations, and local policy on pre/postoperative staging investigations. Several patient scenarios were also presented. Results. 123 of 474 (25.9%) recipients completed the survey. Investigations routinely employed for patients diagnosed with early breast cancer included serological/haematological tests (72% respondents), axillary ultrasound (67%), liver ultrasound (2%), chest radiograph (36%), and computed tomography (CT) (1%). Three areas contributed to decisions to undertake staging by CT scan: tumour size, axillary nodal status, and plan for chemotherapy. There was widespread variation as to criteria for CT staging based on tumour size and nodal status, as well as the choice of staging investigation for the clinical scenarios presented. Conclusions. There remains variation in the use of staging investigations for distant disease in early breastcancer despite available guidelines.

show abstract

“…Le Tableau 5 confronte nos résultats aux principales études de la littérature [2][3][4][5]. La question étudiée ici concerne l'histoire naturelle des cancers du sein de petite taille.…”

Section: Discussionunclassified

“…En effet la première patiente avait subi une mastectomie pour tumeur bifocale et la scintigraphie avait été réalisée en postopératoire. Selon les standards options recommandations (SOR) [3,8], la scintigraphie devrait systématiquement être réalisée avant d'envisager une mastectomie (afin d'éliminer les situations pour lesquelles la chirurgie n'apporte pas de bénéfice). Quant au second cas il s'agit d'un rachis métastatique et symptomatique d'emblée sur une tumeur multifocale, ce qui sort du cadre habituel du dépistage des métastases.…”

Section: Discussionunclassified

Faut-il réaliser une scintigraphie osseuse dans le bilan d’extension des cancers du sein de petite taille ?

Simon¹,

Marret²,

Barillot³

et al. 2009

Gynécologie Obstétrique & Fertilité

View full text Add to dashboard Cite

Preoperative staging of primary breast cancer.A multicentric study

Cited by 63 publications

References 12 publications

Baseline staging tests based on molecular subtype is necessary for newly diagnosed breast cancer

Baseline staging tests based on molecular subtype is necessary for newly diagnosed breast cancer

Staging Investigations in Breast Cancer: Collective Opinion of UK Breast Surgeons

Faut-il réaliser une scintigraphie osseuse dans le bilan d’extension des cancers du sein de petite taille ?

Contact Info

Product

Resources

About